Expert Consensus Documents and the American Heart Association Developed




НазваниеExpert Consensus Documents and the American Heart Association Developed
страница15/15
Дата конвертации06.02.2016
Размер4.1 Mb.
ТипДокументы
источникhttp://kardter.narod.ru/1573.doc
1   ...   7   8   9   10   11   12   13   14   15

150. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for

pulmonary arterial hypertension. Am J Respir Crit Care Med.

2004;169:441–7.

151. Barst RJ, Rich S, Widlitz A, et al. Clinical efficacy of sitaxsentan, an

endothelin-A receptor antagonist, in patients with pulmonary arterial

hypertension: open-label pilot study. Chest. 2002;121:1860–8.

152. Galie N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary

arterial hypertension. J Am Coll Cardiol. 2005;46:529–35.

153. Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the

treatment of pulmonary arterial hypertension: results of the Ambrisentan

in Pulmonary Arterial Hypertension, Randomized,

Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES)

study 1 and 2 (abstr). Circulation. 2008;117:3010 –9.

154. Gilead. Letairis full prescribing information. 2008. Available at:

http://www.letairis.com/full_prescribing_information.html. Accessed

February 11, 2009.

155. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for

pulmonary arterial hypertension. N Engl J Med. 2005;353:2148–57.

156. Hoeper MM, Welte T. Sildenafil citrate therapy for pulmonary

arterial hypertension. N Engl J Med. 2006;354:1091–3.

157. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan

with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

Eur Respir J. 2004;24:353–9.

158. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of

adding inhaled iloprost to existing bosentan in pulmonary arterial

hypertension. Am J Respir Crit Care Med. 2006;174:1257– 63.

159. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled

iloprost with bosentan in patients with idiopathic pulmonary arterial

hypertension. Eur Respir J. 2006;28:691– 4.

160. Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to

long-term intravenous epoprostenol therapy in patients with pulmonary

arterial hypertension: a randomized trial. Ann Intern Med.

2008;149:521–30.

161. Macchia A, Marchioli R, Marfisi R, et al. A meta-analysis of trials of

pulmonary hypertension: a clinical condition looking for drugs and

research methodology. Am Heart J. 2007;153:1037– 47.

161a.Galie N, Manes A, Negro L, et al. A meta-analysis of randomized

controlled trials in pulmonary arterial hypertension. Eur Heart J.

2009;30:394– 403.

162. Avouac J, Wipff J, Kahan A, et al. Effects of oral treatments on

exercise capacity in systemic sclerosis related pulmonary arterial

hypertension: a meta-analysis of randomised controlled trials. Ann

Rheum Dis. 2008;67:808 –14.

163. Ambrisentan (Letairis) for pulmonary arterial hypertension. Med

Lett Drugs Ther. 2007;49:87– 8.

164. Doyle RL, McCrory D, Channick RN, et al. Surgical treatments/

interventions for pulmonary arterial hypertension: ACCP evidencebased

clinical practice guidelines. Chest. 2004;126:63S–71S.

165. Klepetko W, Mayer E, Sandoval J, et al. Interventional and surgical

modalities of treatment for pulmonary arterial hypertension. J Am

Coll Cardiol. 2004;43:73S– 80S.

166. Olsson JK, Zamanian RT, Feinstein JA, et al. Surgical and interventional

therapies for pulmonary arterial hypertension. Semin Respir

Crit Care Med. 2005;26:417–28.

167. Reichenberger F, Pepke-Zaba J, McNeil K, et al. Atrial septostomy

in the treatment of severe pulmonary arterial hypertension. Thorax.

2003;58:797– 800.

168. Rothman A, Sklansky MS, Lucas VW, et al. Atrial septostomy as a

bridge to lung transplantation in patients with severe pulmonary

hypertension. Am J Cardiol. 1999;84:682– 6.

169. Sandoval J, Gaspar J, Pulido T, et al. Graded balloon dilation atrial

septostomy in severe primary pulmonary hypertension. A therapeutic

alternative for patients nonresponsive to vasodilator treatment. J Am

Coll Cardiol. 1998;32:297–304.

170. O’Loughlin AJ, Keogh A, Muller DW. Insertion of a fenestrated

Amplatzer atrial septostomy device for severe pulmonary hypertension.

Heart Lung Circ. 2006;15:275–7.

171. Moscucci M, Dairywala IT, Chetcuti S, et al. Balloon atrial septostomy

in end-stage pulmonary hypertension guided by a novel

intracardiac echocardiographic transducer. Catheter Cardiovasc Interv.

2001;52:530–4.

172. Trulock EP, Edwards LB, Taylor DO, et al. Registry of the

International Society for Heart and Lung Transplantation: twentythird

official adult lung and heart-lung transplantation report—2006.

J Heart Lung Transplant. 2006;25:880 –92.

173. Deleted in proof.

174. Cottini SR, Lerch N, de Perrot M, et al. Risk factors for reperfusion

injury after lung transplantation. Intensive Care Med. 2006;32:557–63.

175. Choong CK, Sweet SC, Guthrie TJ, et al. Repair of congenital heart

lesions combined with lung transplantation for the treatment of

severe pulmonary hypertension: a 13–year experience. J Thorac

Cardiovasc Surg. 2005;129:661–9.

176. Kindo M, Radovancevic B, Gregoric ID, et al. Biventricular support

with the Jarvik 2000 ventricular assist device in a calf model of

pulmonary hypertension. ASAIO J. 2004;50:444 –50.

177. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348:

2007–18.

178. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled

trial of epoprostenol therapy for severe congestive heart failure: the

Flolan International Randomized Survival Trial (FIRST). Am

Heart J. 1997;134:44 –54.

179. Sablotzki A, Czeslick E, Gruenig E, et al. First experiences with the

stable prostacyclin analog iloprost in the evaluation of heart transplant

candidates with increased pulmonary vascular resistance. J Thorac

Cardiovasc Surg. 2003;125:960 –2.

180. Konstam MA, DeNofrio D. Endothelin expression and the progression

of heart failure: exemplifying the vagaries of therapeutic development.

Circulation. 2004;109:143–5.

181. Sutsch G, Kiowski W, Yan XW, et al. Short-term oral endothelinreceptor

antagonist therapy in conventionally treated patients with

symptomatic severe chronic heart failure. Circulation. 1998;98:

2262–8.

182. Mylona P, Cleland JG. Update of REACH-1 and MERIT-HF

clinical trials in heart failure. Cardio.net Editorial Team. Eur J Heart

Fail. 1999;1:197–200.

183. Teerlink JR. Recent heart failure trials of neurohormonal modulation

(OVERTURE and ENABLE): approaching the asymptote of efficacy?

J Card Fail. 2002;8:124 –7.

184. Perez-Villa F, Cuppoletti A, Rossel V, et al. Initial experience with

bosentan therapy in patients considered ineligible for heart transplantation

because of severe pulmonary hypertension. Clin Transplant.

2006;20:239–44.

185. Brauchlin AE, Soccal PM, Rochat T, et al. Severe left ventricular

dysfunction secondary to primary pulmonary hypertension: bridging

therapy with bosentan before lung transplantation. J Heart Lung

Transplant. 2005;24:777– 80.

186. Alaeddini J, Uber PA, Park MH, et al. Efficacy and safety of sildenafil

in the evaluation of pulmonary hypertension in severe heart failure.

Am J Cardiol. 2004;94:1475–7.

187. Lepore JJ, Maroo A, Bigatello LM, et al. Hemodynamic effects of

sildenafil in patients with congestive heart failure and pulmonary

hypertension: combined administration with inhaled nitric oxide.

Chest. 2005;127:1647–53.

188. Lewis GD, Lachmann J, Camuso J, et al. Sildenafil improves exercise

hemodynamics and oxygen uptake in patients with systolic heart

failure. Circulation. 2007;115:59–66.

189. Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise

capacity and quality of life in patients with systolic heart failure and

secondary pulmonary hypertension. Circulation. 2007;116:1555– 62.

190. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure—

abnormalities in active relaxation and passive stiffness of the left

ventricle. N Engl J Med. 2004;350:1953–9.

191. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in

patients with chronic heart failure and preserved left-ventricular

ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:

777–81.

192. Rosenhek R, Rader F, Klaar U, et al. Outcome of watchful waiting in

asymptomatic severe mitral regurgitation. Circulation. 2006;113:

2238–44.

193. Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006

guidelines for the management of patients with valvular heart disease:

a report of the American College of Cardiology/American Heart

Association Task Force on Practice Guidelines (Writing Committee

to Revise the 1998 Guidelines for the Management of Patients With

Valvular Heart Disease): developed in collaboration with the Society

of Cardiovascular Anesthesiologists: endorsed by the Society for

Cardiovascular Angiography and Interventions and the Society of

Thoracic Surgeons. J Am Coll Cardiol. 2006;48:e1–149.

194. Han MK, McLaughlin VV, Criner GJ, et al. Pulmonary diseases and

the heart. Circulation. 2007;116:2992–3005.

195. Higenbottam T. Pulmonary hypertension and chronic obstructive

pulmonary disease: a case for treatment. Proc Am Thorac Soc.

2005;2:12–9.

196. Naeije R. Pulmonary hypertension and right heart failure in chronic

obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2:20 –2.

197. Scharf SM, Iqbal M, Keller C, et al. Hemodynamic characterization

of patients with severe emphysema. Am J Respir Crit Care Med.

2002;166:314 –22.

198. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary

hypertension and chronic obstructive pulmonary disease. Am J Respir

Crit Care Med. 2005;172:189 –94.

199. Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in

advanced COPD candidates for lung volume reduction surgery or

lung transplantation. Chest. 2005;127:1531– 6.

200. Eddahibi S, Chaouat A, Morrell N, et al. Polymorphism of the

serotonin transporter gene and pulmonary hypertension in chronic

obstructive pulmonary disease. Circulation. 2003;108:1839–44.

201. Alp S, Skrygan M, Schmidt WE, et al. Sildenafil improves hemodynamic

parameters in COPD—an investigation of six patients.

Pulm Pharmacol Ther. 2006;19:386 –90.

202. Madden BP, Allenby M, Loke TK, et al. A potential role for

sildenafil in the management of pulmonary hypertension in patients

with parenchymal lung disease. Vascul Pharmacol. 2006;44:372– 6.

203. Maloney JP. Advances in the treatment of secondary pulmonary

hypertension. Curr Opin Pulm Med. 2003;9:139–43.

204. Ryu JH, Krowka MJ, Pellikka PA, et al. Pulmonary hypertension in

patients with interstitial lung diseases. Mayo Clin Proc. 2007;82:

342–50.

205. Nathan SD, Shlobin OA, Ahmad S, et al. Pulmonary hypertension

and pulmonary function testing in idiopathic pulmonary fibrosis.

Chest. 2007;131:657– 63.

206. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic

assessment of pulmonary hypertension in patients with advanced lung

disease. Am J Respir Crit Care Med. 2003;167:735– 40.

207. Leuchte HH, Neurohr C, Baumgartner R, et al. Brain natriuretic

peptide and exercise capacity in lung fibrosis and pulmonary hypertension.

Am J Respir Crit Care Med. 2004;170:360 –5.

208. Shorr AF, Helman DL, Davies DB, et al. Pulmonary hypertension in

advanced sarcoidosis: epidemiology and clinical characteristics. Eur

Respir J. 2005;25:783– 8.

209. Fisher KA, Serlin DM, Wilson KC, et al. Sarcoidosis-associated

pulmonary hypertension: outcome with long-term epoprostenol

treatment. Chest. 2006;130:1481– 8.

210. Atwood CW Jr., McCrory D, Garcia JG, et al. Pulmonary artery

hypertension and sleep-disordered breathing: ACCP evidence-based

clinical practice guidelines. Chest. 2004;126:72S–7S.

211. Moser KM, Bloor CM. Pulmonary vascular lesions occurring in

patients with chronic major vessel thromboembolic pulmonary hypertension.

Chest. 1993;103:685–92.

212. Bonderman D, Jakowitsch J, Adlbrecht C, et al. Medical conditions

increasing the risk of chronic thromboembolic pulmonary hypertension.

Thromb Haemost. 2005;93:512– 6.

213. Jamieson SW, Kapelanski DP, Sakakibara N, et al. Pulmonary

endarterectomy: experience and lessons learned in 1,500 cases. Ann

Thorac Surg. 2003;76:1457– 62.

214. Kim NH. Assessment of operability in chronic thromboembolic

pulmonary hypertension. Proc Am Thorac Soc. 2006;3:584–8.

215. Feinstein JA, Goldhaber SZ, Lock JE, et al. Balloon pulmonary

angioplasty for treatment of chronic thromboembolic pulmonary

hypertension. Circulation. 2001;103:10 –3.

216. Bresser P, Pepke-Zaba J, Jais X, et al. Medical therapies for chronic

thromboembolic pulmonary hypertension: an evolving treatment

paradigm. Proc Am Thorac Soc. 2006;3:594–600.

217. Kerr KM, Rubin LJ. Epoprostenol therapy as a bridge to pulmonary

thromboendarterectomy for chronic thromboembolic pulmonary hypertension.

Chest. 2003;123:319 –20.

218. Malouf JF, Enriquez-Sarano M, Pellikka PA, et al. Severe pulmonary

hypertension in patients with severe aortic valve stenosis: clinical

profile and prognostic implications. J Am Coll Cardiol. 2002;40:

789–95.

219. Vincens JJ, Temizer D, Post JR, et al. Long-term outcome of cardiac

surgery in patients with mitral stenosis and severe pulmonary hypertension.

Circulation. 1995;92:II137– 42.

220. Yang H, Davidson WR Jr., Chambers CE, et al. Preoperative

pulmonary hypertension is associated with postoperative left ventricular

dysfunction in chronic organic mitral regurgitation: an echocardiographic

and hemodynamic study. J Am Soc Echocardiogr. 2006;

19:1051–5.

221. Costard-Jackle A, Fowler MB. Influence of preoperative pulmonary

artery pressure on mortality after heart transplantation: testing of

potential reversibility of pulmonary hypertension with nitroprusside is

useful in defining a high risk group. J Am Coll Cardiol. 1992;19:48–54.

222. Aris A, Camara ML. As originally published in 1988: long-term

results of mitral valve surgery in patients with severe pulmonary

hypertension. Updated in 1996. Ann Thorac Surg. 1996;61:1583– 4.

223. Umesan CV, Kapoor A, Sinha N, et al. Effect of Inoue balloon mitral

valvotomy on severe pulmonary arterial hypertension in 315 patients

with rheumatic mitral stenosis: immediate and long-term results.

J Heart Valve Dis. 2000;9:609 –15.

224. Argenziano M, Choudhri AF, Moazami N, et al. Randomized,

double-blind trial of inhaled nitric oxide in LVAD recipients with

pulmonary hypertension. Ann Thorac Surg. 1998;65:340 –5.

225. Chang PP, Longenecker JC, Wang NY, et al. Mild vs severe

pulmonary hypertension before heart transplantation: different effects

on posttransplantation pulmonary hypertension and mortality.

J Heart Lung Transplant. 2005;24:998 –1007.

226. Beck JR, Mongero LB, Kroslowitz RM, et al. Inhaled nitric oxide

improves hemodynamics in patients with acute pulmonary hypertension

after high-risk cardiac surgery. Perfusion. 1999;14:37– 42.

227. Santini F, Casali G, Franchi G, et al. Hemodynamic effects of

inhaled nitric oxide and phosphodiesterase inhibitor (dipyridamole)

on secondary pulmonary hypertension following heart valve surgery in

adults. Int J Cardiol. 2005;103:156–63.

228. Rea RS, Ansani NT, Seybert AL. Role of inhaled nitric oxide in adult

heart or lung transplant recipients. Ann Pharmacother. 2005;39:913–7.

229. Lowson SM, Doctor A, Walsh BK, et al. Inhaled prostacyclin for the

treatment of pulmonary hypertension after cardiac surgery. Crit Care

Med. 2002;30:2762– 4.

230. Fattouch K, Sbraga F, Bianco G, et al. Inhaled prostacyclin, nitric

oxide, and nitroprusside in pulmonary hypertension after mitral valve

replacement. J Card Surg. 2005;20:171– 6.

231. Theodoraki K, Tsiapras D, Tsourelis L, et al. Inhaled iloprost in

eight heart transplant recipients presenting with post-bypass acute

right ventricular dysfunction. Acta Anaesthesiol Scand. 2006;50:

1213–7.

232. Madden BP, Sheth A, Ho TB, et al. Potential role for sildenafil in

the management of perioperative pulmonary hypertension and right

ventricular dysfunction after cardiac surgery. Br J Anaesth. 2004;93:

155–6.

233. Trachte AL, Lobato EB, Urdaneta F, et al. Oral sildenafil reduces

pulmonary hypertension after cardiac surgery. Ann Thorac Surg.

2005;79:194 –7.

234. Carteaux JP, Roux S, Siaghy M, et al. Acute pulmonary hypertension

after cardiopulmonary bypass in pig: the role of endogenous endothelin.

Eur J Cardiothorac Surg. 1999;15:346 –52.

235. Friedman WF. Proceedings of National Heart, Lung, and Blood

Institute pediatric cardiology workshop: pulmonary hypertension.

Pediatr Res. 1986;20:811–24.

236. Roberts KE, McElroy JJ, Wong WP, et al. BMPR2 mutations in

pulmonary arterial hypertension with congenital heart disease. Eur

Respir J. 2004;24:371– 4.

237. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary

pulmonary hypertension in children. Circulation. 1999;99:1197–208.

238. Yung D, Widlitz AC, Rosenzweig EB, et al. Outcomes in children

with idiopathic pulmonary arterial hypertension. Circulation. 2004;

110:660 –5.

239. Rosenzweig EB, Ivy DD, Widlitz A, et al. Effects of long-term

bosentan in children with pulmonary arterial hypertension. J Am Coll

Cardiol. 2005;46:697–704.
1   ...   7   8   9   10   11   12   13   14   15

Похожие:

Expert Consensus Documents and the American Heart Association Developed iconCapitalism and the American economy 4 The American population 5 Section 2: The immigration debate

Expert Consensus Documents and the American Heart Association Developed iconTable 60. List of kase internal documents and amendments to kase internal documents, approved in 2010

Expert Consensus Documents and the American Heart Association Developed iconLatin American History and Culture: Series 1: Parts 1-7: The Yale University Collection of Latin American Manuscripts

Expert Consensus Documents and the American Heart Association Developed iconIt celebrates independence of American colonies from the British. It is the anniversary of the signing of the Declaration of Independence in 1776. The oldest American holiday is Thanksgiving Day

Expert Consensus Documents and the American Heart Association Developed iconThe Effect of Caffeine on Heart Rate

Expert Consensus Documents and the American Heart Association Developed iconText S1: Results of the Delphi consensus survey

Expert Consensus Documents and the American Heart Association Developed iconLinking Word Documents. pdf files

Expert Consensus Documents and the American Heart Association Developed iconThis symposium addresses a question of increasing urgency for public art. Although a degree of consensus has evolved in recent years over the issue of good

Expert Consensus Documents and the American Heart Association Developed iconLast date for submission of documents for scholars selected in 7th meeting is 5th May, 2008

Expert Consensus Documents and the American Heart Association Developed iconAami association for the Advancement of Medical Instrumentation

Разместите кнопку на своём сайте:
Документы


База данных защищена авторским правом ©kzdocs.docdat.com 2012
обратиться к администрации
Документы
Главная страница